Distalmotion has reached key enrollment milestones in two US pivotal trials for its DEXTER robotic surgery system: RAVEN for ventral hernia repair and SPARO for sacrocolpopexy. RAVEN has surpassed 25% enrollment, while SPARO is nearing the halfway mark. The company also announced FDA approval for its REAL-M trial, evaluating DEXTER in myomectomy, set to begin enrolling in Q4 2025.
This rapid succession of trial activations and enrollment progress underscores Distalmotion’s aggressive push to expand DEXTER’s US indications beyond its current clearances for inguinal hernia repair and cholecystectomy. The targeted procedures – ventral hernia repair, sacrocolpopexy, and myomectomy – represent high-volume opportunities in the outpatient setting, aligning with the company’s strategy to position DEXTER as a cost-effective robotic solution for ambulatory surgical centers (ASCs) and hospital outpatient departments (HOPDs). This focus on outpatient procedures addresses the growing market demand for minimally invasive surgery in lower-cost settings.
The strategy contrasts with the prevailing trend among established robotic surgery players who primarily target complex inpatient procedures. Distalmotion is betting that DEXTER’s smaller footprint, mobility between operating rooms, and compatibility with existing laparoscopic tools will resonate with cost-conscious ASCs seeking a less disruptive and more affordable entry point into robotic surgery. This approach directly addresses the capital expenditure hurdles and workflow integration challenges that have hindered broader robotic adoption in outpatient settings.
The success of this strategy hinges on demonstrating comparable clinical outcomes to existing robotic platforms while maintaining the promised cost advantages. For sites, the key considerations will be the learning curve for surgical teams, the system’s reliability in a high-turnover environment, and the long-term cost of disposables versus reusable instruments. For sponsors and CROs, the challenge lies in efficiently executing trials across a fragmented ASC landscape, with its inherent variability in staffing, infrastructure, and data capture capabilities.
Looking ahead, Distalmotion’s progress will be measured not just by trial outcomes but also by market penetration in the increasingly competitive outpatient robotics sector. Investors will be watching closely for data on procedure times, conversion to open surgery rates, and ultimately, the total cost of care delivered using the DEXTER system. The company’s ability to secure favorable reimbursement coding and establish efficient distribution and service networks will be critical for long-term success. Whether this streamlined approach can reshape the surgical robotics landscape remains to be seen.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
Innovation at the Intersection of Surgery, Inflammation, and AI in Clinical Trials
1 month ago[…] Swiss medtech company Distalmotion is making waves with the expansion of clinical trials for its robotic-assisted Dexter Surgical System. Initially targeted at general surgery, the system is now being evaluated for gynecological procedures as well. Designed to blend the dexterity of robotics with surgeon-controlled laparoscopic techniques, Dexter offers real-time flexibility without the need for complex docking and redocking processes. With trials underway across multiple European centers, the system aims to reduce surgical invasiveness, improve precision, and enhance patient outcomes. Its dual focus on general and gynecological surgeries marks a major step forward in streamlining robotic solutions for broader clinical applications (source). […]